Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

Source document· January 23, 2026

Communiqué de presse : L’amlitelimab de Sanofi confirme son potentiel dans la dermatite atopique

View original at globenewswire.com

Communiqué de presse : L’amlitelimab de Sanofi confirme son potentiel dans la dermatite atopique L’amlitelimab de Sanofi confirme son potentiel dans la dermatite atopique Dans l'étude de phase 3 SHORE, l'amlitelimab en association avec des traitements topiques a atteint tous les critères d'évaluation principaux et seco…

Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

Global regulatory submissions are planned for second half of 2026
80% confidence
These results validate the new mechanism of action of amlitelimab, which blocks OX40 ligand without destroying T cells, and its ability to normalize the immune system over time
80% confidence
Two additional phase 3 studies, AQUA and ESTUARY, are expected to publish results in second half of 2026
80% confidence
The complete data observed to date reinforces confidence in amlitelimab's potential to offer both every-12-week dosing from treatment start and progressive efficacy through week 52
80% confidence
Amlitelimab's safety and efficacy profiles have not been evaluated by any regulatory authority; the product is currently in clinical development
80% confidence